TrialClinical pharmacology and therapeutics2012

Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension.

N Fujimura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.